case study [transfusion medicine | hematology | chemistry | immunology] 
Physical Examination
Normal except for mild abdominal distension; tympanic to percussion, jaundice, petechiae on both thighs and lower trunk, bilateral lower extremity edema, and severe weakness of the lower extremities.
Principal Laboratory Findings
[T1] and [T2] .
Results of Other Diagnostic Procedures
Computed tomography (CT) scans of her chest and abdomen demonstrated bilateral ground-glass infiltrates and ascites, respectively. 
Principal Non-Immunohematology Laboratory Findings

2.
Ground glass pulmonary infiltrates are consistent with our patient's URTI, complicated by pneumonia. Neutrophilia, electrolyte disturbances (ie, potassium and chloride), protein and blood in the urine, increased BUN and ammonia, and markedly increased values for a variety of liver function tests were most likely due to the combination of the patient's urinary tract and upper respiratory tract infections, worsening renal and liver function, and a hemolytic anemia induced by the patient's high titer of anti-I antibody. Intravascular hemolysis would also contribute to the presence of hemoglobin in the urine and a markedly increased serum LD concentration from release of the LD-1 and LD-2 isoenzymes found in relatively high concentration in red blood cells (RBCs). Because cold autoantibodies may occur normally in some individuals and in others as a result of a variety of conditions [eg, mycoplasma pneumonia (>80% of cases), listeriosis, infectious mononucleosis, acute CMV infection, subacute bacterial endocarditis, malaria, trypanosomiasis, syphilis, collagen vascular disease, and hematolymphoid malignancies], the presence of these autoantibodies alone may not account for a patient's anemia. Moreover, anti-I and anti-H are the most frequently encountered unexpected antibodies in serologic tests performed at room temperature. Therefore, additional laboratory tests are needed to further define the nature of the patient's anemia. These tests might include: peripheral blood and bone marrow examination for the presence of abnormal cells characteristic of hematolymphoid malignancies; hemoglobin electrophoresis for hemoglobinopathies; DAT for evidence of in vivo RBC sensitization by circulating antibody, suggestive of immune-mediated hemolytic anemia; cold autoantibody thermal amplitude studies; cyroglobulin testing, including clonality by immunofixation electrophoresis (IFE) of any cryoglobulin detected by routine protein electrophoresis; the Ham's test for paroxysmal nocturnal hemoglobinuria (PNH); the osmotic fragility test for hereditary spherocytosis and red cell membrane abnormalities; quantitative serum haptoglobin determination to assess the extent of any intravascular hemolysis; the ANA test for collagen vascular disease; and a variety of other antibody tests indicative of infection by a specific bacterial or viral organism. Cryoglobulin testing and testing for cryoglobulin-like antibodies (eg, P1 blood system antibodies to RBC antigens), including assessment of clonality by IFE of any cryoglobulin detected by routine protein electrophoresis, may also be useful. The majority of cold agglutinins due to infection with Mycoplasma pneumoniae are polyclonal (eg, IgM anti-I), while those that occur secondary to hematolymphoid malignancies are typically monoclonal. Test results used to substantiate the intravascular nature of a hemolytic anemia include decreased serum haptoglobin and increased indirect bilirubin and LD concentrations, hemosiderinuria, and hemoglobinuria. Moreover, examination of a stained peripheral blood smear might demonstrate polychromatophilia, anisocytosis/poikilocytosis, macrocytosis, spherocytes, and red cell fragments consistent with ongoing hemolysis due to a specific cause.
3.
Many of the tests indicated above were performed on our patient; however, the results of these tests did not entirely explain the source or cause of the patient's cold autoantibody, hemolytic anemia, and markedly abnormal liver function tests. In this patient, while M. pneumonia was highly suspected due to recurrent URIs, it was excluded by a negative serum M. pneumoniae antibody titer. In addition, negative immunoglobulin M (IgM) antibody titers for CMV and Epstein-Barr virus excluded cytomegalovirus infection or infectious mononucleosis as the 
T2
cause of our patient's acute illness. Moreover, collagen vascular disease was excluded by a negative ANA test. On the other hand, this patient's positive DAT due to complement (C3) (with subsequent identification of the cold-reactive autoantibody, anti-I) in our patient's serum was consistent with an autoantibodyinduced hemolytic anemia. This finding alone, however, does not explain our patient's markedly elevated liver function tests. Our patient's markedly elevated liver enzymes with high total and direct bilirubin values suggest the presence of liver disease, including that caused by hematolymphoid malignancies. 1 Thus, our patient underwent a transcutaneous liver biopsy in an attempt to explain her ascites and the abnormal laboratory test results. Pertinent biopsy findings included the presence of a marked, diffuse (primarily intracanalicular) bile stasis and portal tract expansion by lymphocytes not associated with piecemeal necrosis. Immunohistochemical analysis demonstrated a mature lymphoid population expressing CD20, bcl-2, and CD43 cell surface markers, while staining negative for CD3 and CD23. These findings, in conjunction with the histopathological findings from the liver biopsy, were highly suggestive of B-cell lymphoma.
Most likely diagnosis: Cold autoantibody-induced hemolytic anemia secondary to B-cell lymphoma involving the liver.
5.
Being kept in a warm environment, drug therapy, splenectomy, plasma exchange, and monoclonal antibody therapy. It is important that the patient be kept in a warm environment and that all blood and/or blood components and intravenous fluids administered to the patient be warmed to normal body temperature to avoid or limit in vivo RBC sensitization by the patient's cold autoantibody, especially during circulation through distal areas. In addition, high-dose steroid therapy (not helpful in the majority of cases because cold autoantibodies are usually of the IgM class of immunoglobulins), splenectomy (usually ineffective because sensitized RBCs can also be cleared by the liver), and plasma exchange (helpful only as a temporizing measure in acute situations because antibodies removed during this process are eventually replaced) are other treatment options. Cold autoantibody-induced hemolytic anemia, secondary to B-cell lymphoma, may show improvement following the administration of the monoclonal antibody (anti-CD20) preparation, Rituximab. [2] [3] [4] 6. Rituximab is a bioengineered hybrid murine/human monoclonal antibody directed against the CD20 antigen found on both normal and malignant B lymphocytes. The binding of Rituximab promotes the immune-mediated destruction of B lymphocytes. Rituximab is given at a dose of 375 mg/m 2 by intravenous infusion once per week for a period of 4 weeks. Serious side effects include hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, and cardiogenic shock. Other adverse reactions are tumor lysis syndrome, severe mucocutaneous reactions, and prolonged impairment of the humoral immune system leading to an increased risk of viral and bacterial infections. [2] [3] [4] Patient's Treatment and Course Rituximab therapy was initiated in an attempt to decrease or halt the production of the circulating cold autoantibody. Based on serial antibody screens, the treatment was effective as no demonstrable cold autoantibody was detectable following 12 days of therapy. Unfortunately, the patient succumbed to complications stemming from a disseminated Pseudomonas infection 4 weeks after the initiation of Rituximab therapy.
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